Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer

NCT04163237 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Advanced Liver Cancer

Interventions

DRUG: PD-1
DRUG: Sorafenib

Sponsor

Guangxi Medical University